-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
MediPharm Labs Enters Into $4.68M Purchase Agreement For The Sale Of Australian Facility
MediPharm Labs Enters Into $4.68M Purchase Agreement For The Sale Of Australian Facility
MediPharm Labs Corp. (OTCQX:MEDIF) (TSX:LABS) (FSE:MLZ) a pharmaceutical company specialized in precision-based cannabinoids, has entered into a share prchase agreement with OneLife Botanicals PTY for the sale of MediPharm Labs Australia Pty Ltd, a wholly-owned subsidiary of the company, for a minimum value of AU$6.9 million ($4.68 million). The agreement is subject to routine conditions and is anticipated to close within 90 days.
The agreement includes the assets of MPLA, specialized licensing, operational knowledge, and Australian and New Zealand customers currently served from that facility. All international contracts outside of Australia and New Zealand will remain with MediPharm Labs and be serviced from our Barrie GMP facility.
In July 2021, MediPharm Labs was the first purpose-built cannabis facility to receive a pharmaceutical Drug Establishment License. Awarded by Health Canada, this license is recognized in over 50 countries as part of the Pharmaceutical Inspection Co-operation Scheme (PIC/S). At this time, the company has completed a review of its international manufacturing platform and identified significant potential savings in moving all domestic and international manufacturing to the Canadian facility.
After an extensive sale process, the agreement with OneLife Botanicals was identified as a strategic fit for both parties. OneLife Botanicals is an emerging leader in Australia region for cannabis-based wellness and medical products, with plans to launch OTC CBD products across Australia. Purchasing the MPLA facility expedites OneLife Botanicals' timing to commercialization. The company and OneLife Botanicals will also enter into a transition services agreement to allow for the two companies to smoothly transition products and services produced in the facility, and to work together on future commercial opportunities.
David Pidduck, CEO of MediPharm Labs stated, "This sale represents a major milestone for MediPharm Labs as it continues to focus on rightsizing the business to achieve profitability. As we look to maintain our strong cash balance, this transaction paired with corporate restructuring completed in June 2022 should allow us to reduce our quarterly burn rate as we improve sales.
I want to personally thank our Australian team. This group of professionals are trailblazers in the Australian and international medical cannabis market, achieving major milestones such as multiple customer product launches and our first deliveries to Germany. OneLife Botanicals is gaining one of the most capable medical cannabis manufacturing teams in Australia."
Photo by Richard T on Unsplash
Related News
BREAKING: Brazil Supreme Court Authorizes Citizens To Grow Medicinal Cannabis
MediPharm Labs Q1 Revenue Slightly Drops, Here Are The Details
MediPharm Labs Launches CBG And Water-Soluble CBN:THC Products
MediPharm Labs Corp. (OTCQX:MEDIF) (TSX:LABS) (FSE:MLZ) a pharmaceutical company specialized in precision-based cannabinoids, has entered into a share prchase agreement with OneLife Botanicals PTY for the sale of MediPharm Labs Australia Pty Ltd, a wholly-owned subsidiary of the company, for a minimum value of AU$6.9 million ($4.68 million). The agreement is subject to routine conditions and is anticipated to close within 90 days.
醫療藥業實驗室公司(多倫多證券交易所股票代碼:MEDIF)(多倫多證券交易所股票代碼:LABS)(多倫多證券交易所股票代碼:MLZ)是一家專門生產精密大麻類藥物的製藥公司,該公司已與s野兔pRChasea與OneLife Botanals Pty達成協議對於銷售的澳大利亞醫藥實驗室私人有限公司,該公司的全資附屬公司,最低價值為Au(自動)$6.9 百萬(468萬美元)。該協議受到例行條件的限制,預計將在90天內完成。
The agreement includes the assets of MPLA, specialized licensing, operational knowledge, and Australian and New Zealand customers currently served from that facility. All international contracts outside of Australia and New Zealand will remain with MediPharm Labs and be serviced from our Barrie GMP facility.
該協議包括M解放軍的資產、專業許可、運營知識以及目前由該設施提供服務的澳大利亞和新西蘭客户。澳大利亞和新西蘭以外的所有國際合同都將保留在醫療製藥實驗室,並由我們的巴里GMP設施提供服務。
In July 2021, MediPharm Labs was the first purpose-built cannabis facility to receive a pharmaceutical Drug Establishment License. Awarded by Health Canada, this license is recognized in over 50 countries as part of the Pharmaceutical Inspection Co-operation Scheme (PIC/S). At this time, the company has completed a review of its international manufacturing platform and identified significant potential savings in moving all domestic and international manufacturing to the Canadian facility.
2021年7月,MediPharm實驗室成為第一個接受藥物治療的專門建造的大麻設施《藥品經營許可證》。由加拿大衞生部頒發,這一許可證在50多個國家和地區被公認為藥檢合作計劃(圖片S)。目前,該公司已經完成了對其國際製造平臺的審查,並確定了將所有國內和國際製造轉移到加拿大工廠的顯著節省潛力。
After an extensive sale process, the agreement with OneLife Botanicals was identified as a strategic fit for both parties. OneLife Botanicals is an emerging leader in Australia region for cannabis-based wellness and medical products, with plans to launch OTC CBD products across Australia. Purchasing the MPLA facility expedites OneLife Botanicals' timing to commercialization. The company and OneLife Botanicals will also enter into a transition services agreement to allow for the two companies to smoothly transition products and services produced in the facility, and to work together on future commercial opportunities.
經過廣泛的銷售過程,與OneLife Botanals的協議被確定為雙方的戰略合適人選。OneLife Botanals是澳大利亞地區大麻保健和醫療產品的新興領先者,計劃推出澳大利亞的場外CBD產品。購買MPLA設施加快了OneLife Botanals商業化的時機。該公司和OneLife Botanals還將簽訂一項過渡服務協議,使兩家公司能夠順利過渡該設施生產的產品和服務,並就未來的商業機會進行合作。
David Pidduck, CEO of MediPharm Labs stated, "This sale represents a major milestone for MediPharm Labs as it continues to focus on rightsizing the business to achieve profitability. As we look to maintain our strong cash balance, this transaction paired with corporate restructuring completed in June 2022 should allow us to reduce our quarterly burn rate as we improve sales.
大衞·皮達克,醫藥實驗室首席執行官表示:“此次出售對醫藥實驗室來説是一個重要的里程碑,因為該實驗室將繼續專注於調整業務以實現盈利。在我們尋求保持強大的現金平衡的同時,這筆交易與2022年6月完成的公司重組相結合,將使我們能夠在提高銷售額的同時降低季度燒損率。
I want to personally thank our Australian team. This group of professionals are trailblazers in the Australian and international medical cannabis market, achieving major milestones such as multiple customer product launches and our first deliveries to Germany. OneLife Botanicals is gaining one of the most capable medical cannabis manufacturing teams in Australia."
我想親自感謝我們的澳大利亞隊。這羣專業人士是澳大利亞和國際醫用大麻市場的開拓者,實現了重大里程碑,如推出多個客户的產品和我們向德國的第一批交貨。OneLife Botanals正在獲得澳大利亞最有能力的醫用大麻製造團隊之一。
Photo by Richard T on Unsplash
理查德·T在Unspash上的照片
Related News
相關新聞
BREAKING: Brazil Supreme Court Authorizes Citizens To Grow Medicinal Cannabis
突破:巴西最高法院授權公民種植藥用大麻
MediPharm Labs Q1 Revenue Slightly Drops, Here Are The Details
醫藥實驗室第一季度收入略有下降,以下是詳細信息
MediPharm Labs Launches CBG And Water-Soluble CBN:THC Products
梅迪帕姆實驗室推出CBG和水溶性CBN:THC產品
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧